View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 18, 2021updated 12 Jul 2022 11:06am

LoA Update: Merck’s chikungunya fever vaccine trial sees 11-point spike in chances to transition to next stage after Phase II status update

Merck’s chikungunya vaccine V-184 saw its Phase Transition Success Rate (PTSR) leap 11 points to 74% after its Phase II trial completed.

By William Newton

Merck’s chikungunya vaccine V-184 saw its Phase Transition Success Rate (PTSR) leap 11 points to 74% after its Phase II trial completed. The PTSR score change occurred on 15 June after ClinicalTrials.gov updated the trial from suspended to completed on 9 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Vienna, Austria-based Themis Biosciences, a Merck subsidiary, ran the 41-patient Phase II in collaboration with the Walter Reed Army Institute of Research, according to ClinicalTrials.gov. The placebo-controlled study tested the safety and chikungunya antibody titer of two doses of a live recombinant measles-vectored chikungunya vaccine (MV-CHIK) delivered four weeks apart. Chikungunya fever is a viral, mosquito-borne disease most commonly found in Asia and Africa. Themis is also developing vaccines for Zika and Lassa fever, according to the company website.

The Phase II update resulted in a modest one-point bump to the drug’s Likelihood of Approval (LoA), which rose to 7%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Merck has a market cap of $193.98bn.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena